Alternatives for non-PDE5-I responders in erectile dysfunction patients
Related Experiment Video
Updated: Jul 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
1Andrology, Urology, Continence Center, Gleneagles Hospital, Singapore. tphphcl@pacific.net.sg
Abstract:
The management of a patient presenting with erectile dysfunction encompasses the classical complete history, physical examination, blood work-up, and radiographic or sonographic studies. Often the history directs the treatment toward counseling and psychosexual therapy with use of PDE5 inhibitors as the first-line approach. When the latter fails, other oral erectogenic drugs, vasoactive injectables, creams, or hormone treatment is given based on the work-up. In certain cases of vasculogenic etiology, ligation of venous leakers or revascularization of the penis may be appropriate. The port of last call is the penile prosthetic implant. The implant, however, is an all or none option, requiring surgical destruction of the corporal tissue before implantation, and once inserted, it the implant must function forever. Explantation because of infection or for other reasons renders the patient impotent unless another implant is inserted. The Brindley penile drug delivery implant provides a solution that, when no longer needed, can be removed and returns the penis to its preimplant status. If a vasoactive drug like prostaglandin works, the candidate is deemed suitable. The device uses sodium nitroprusside. Through minimal access (day) surgery, the magnitude of which is only a stage slightly higher than integumentary surgery and done within 20-30 minutes, this is an advance that is presented herewith with a full account of the components, preoperative preparation, drug filling and refilling, and a step by step account of the surgery.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...